^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    reozalimab (IBI318)

    i
    Other names: IBI318, IBI 318, LY3434172
    Associations

    News

    Trials
    Company:
    Eli Lilly, Innovent Biologics
    Drug class:
    PD1 inhibitor, PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. (clinicaltrials.gov)
    P2, N=120, Recruiting, Hunan Province Tumor Hospital | Phase classification: P1 --> P2
    Phase classification
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    11ms
    A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer (clinicaltrials.gov)
    P1, N=10, Terminated, Eli Lilly and Company | Completed --> Terminated; Study did not achieve its primary objective due to early termination of the study
    Trial termination
    |
    reozalimab (IBI318)
    11ms
    Octreotide plus IBI-318 plus anlotinib in the treatment of multiple neuroendocrine metastases of unknown primary lesions: a case report. (PubMed, Front Oncol)
    This report presented a patient who received octreotide plus IBI-318 plus anlotinib as a second-line treatment for multiple metastatic NETs of unknown primary lesions after the failure of octreotide plus everolimus. Octreotide plus IBI318 plus anlotinib achieved benefits in a patient with advanced NETs of unknown primary lesions after first-line treatment failure, even though with low PD-L1 expression. This case suggests that combining SSAs, TKIs and PD-1/PD-L1 inhibitors could be an alternative second-line treatment for patients with advanced, well-differentiated NETs.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Focus V (anlotinib) • everolimus • reozalimab (IBI318)
    almost2years
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P1; Trial completion date: Nov 2023 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    over2years
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P1; Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    over3years
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P1; Trial primary completion date: Apr 2022 --> Mar 2023
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    over3years
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P1; N=30 --> 100
    Enrollment change
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    almost4years
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P1, N=30, Recruiting, Hunan Province Tumor Hospital | Phase classification: P2 --> P1 | Initiation date: Mar 2021 --> Aug 2021
    Clinical • Phase classification • Trial initiation date
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    almost5years
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P2, N=30, Recruiting, Hunan Province Tumor Hospital
    Clinical • New P2 trial
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)